Biomarker Discovery and Validation: Statistical Considerations
Open Access
- 1 February 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 16 (4), 537-545
- https://doi.org/10.1016/j.jtho.2021.01.1616
Abstract
No abstract availableFunding Information
- National Institutes of Health
- National Cancer Institute
This publication has 29 references indexed in Scilit:
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Biomarker studies: a call for a comprehensive biomarker study registryNature Reviews Clinical Oncology, 2011
- Tackling the widespread and critical impact of batch effects in high-throughput dataNature Reviews Genetics, 2010
- Sources of Bias in Specimens for Research About Molecular Markers for CancerJournal of Clinical Oncology, 2010
- Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersJNCI Journal of the National Cancer Institute, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working GroupGenetics in Medicine, 2009
- Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study DesignJNCI Journal of the National Cancer Institute, 2008
- Randomized Phase III Clinical Trial Designs for Targeted AgentsClinical Cancer Research, 2008
- Statistical significance for genomewide studiesProceedings of the National Academy of Sciences of the United States of America, 2003